CCR2+ Monocyte Reprogramming via IL-10 Enhancement for CNS Immune Privilege Res…

Rather than depleting CCR2+ monocytes, this hypothesis proposes reprogramming their phenotype through targeted IL-10 pathway enhancement to restore CNS immune privilege. CCR2+ monocytes recruited to neuroinflammatory sites can be polarized toward an M2-like, tissue-repair phenotype through localized IL-10 overexpression or IL-10 receptor signaling amplification. This approach leverages the natural trafficking of CCR2+ monocytes along the CCL2 gradient while converting them from pro-inflammatory effectors into immune privilege guardians. Specifically, viral vector-mediated IL-10 delivery or pharmacological IL-10R agonists would be administered to CNS lesion sites where CCR2+ monocytes accumulate. The reprogrammed monocytes would then secrete anti-inflammatory cytokines, promote regulatory T cell expansion, and establish local immune suppressive microenvironments that recapitulate physiological CNS immune privilege. This mechanism preserves the beneficial surveillance functions of monocyte-derived cells while eliminating their pathological inflammatory contributions. The intervention targets the IL-10/IL-10R axis rather than CCR2 itself, maintaining monocyte recruitment but fundamentally altering their functional program. Evidence would focus on measuring phenotypic markers of M2 polarization (Arg1, IL-10, TGF-β production) in CNS-infiltrating CCR2+ cells, quantifying local Treg populations, and assessing restoration of blood-brain barrier integrity. This approach offers potential advantages over depletion strategies by maintaining immune surveillance capacity while redirecting inflammatory responses toward tissue repair and immune privilege maintenance.